1.
Clin Infect Dis
; 60(12): 1860-3, 2015 Jun 15.
Article
in English
| MEDLINE
| ID: mdl-25722197
ABSTRACT
In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.